- MarketWatch•19 days ago
Shares of biotech KaloBios Pharmaceuticals Inc. surged 8% Thursday, after the company reported positive guidance from a meeting with the U.S. Food and Drug Administration regarding its benznidazole, a ...
- GlobeNewswire•19 days ago
Minutes received from recent FDA meeting on benznidazole 505 regulatory pathway using existing safety and efficacy data is acceptable Benznidazole eligible for neglected tropical disease priority review ...
- GlobeNewswire•last month
BRISBANE, Calif., Dec. 13, 2016-- KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, ...
KBIO: Summary for KALOBIOS PHARMACEU COM USD0.001 - Yahoo Finance
KaloBios Pharmaceuticals, Inc. (KBIO)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
|Day's range||3.40 - 3.64|
|52-week range||2.17 - 5.21|
Trade prices are not sourced from all markets
|PE ratio (TTM)||-0.69|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|